Covered recipient · General Payments record
JENNIFER SOUNG
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$271,237.24
287 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $141,335.00 | 64 |
| Consulting Fee | $112,747.75 | 44 |
| Travel and Lodging | $11,670.53 | 46 |
| Food and Beverage | $5,396.96 | 132 |
| Education | $87.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $51,506.23 | 51 |
| UCB, Inc. | $43,371.37 | 63 |
| Amgen Inc. | $33,944.41 | 13 |
| Janssen Scientific Affairs, LLC | $32,141.15 | 26 |
| Regeneron Healthcare Solutions, Inc. | $24,679.39 | 19 |
| GENZYME CORPORATION | $18,309.84 | 6 |
| LEO Pharma Inc. | $17,448.11 | 12 |
| AbbVie Inc. | $15,682.03 | 24 |
| Janssen Biotech, Inc. | $11,574.19 | 21 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $9,109.50 | 13 |
| Novartis Pharmaceuticals Corporation | $6,755.66 | 16 |
| Eli Lilly and Company | $2,800.00 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,480.00 | 1 |
| Incyte Corporation | $790.26 | 4 |
| SANOFI-AVENTIS U.S. LLC | $259.92 | 4 |
| PFIZER INC. | $178.11 | 8 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $115.13 | 1 |
| E.R. Squibb & Sons, L.L.C. | $39.68 | 1 |
| Galderma Laboratories, L.P. | $36.93 | 2 |
| VYNE Pharmaceuticals Inc. | $15.33 | 1 |
Page 2 of 6; records 51–100 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JENNIFER SOUNG
NPI 1346408226 · CMS profile ID 151911
Allopathic & Osteopathic Physicians / Dermatology
SANTA ANA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1346408226?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JENNIFER SOUNG, NPI 1346408226, CMS profile ID 151911. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346408226?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). JENNIFER SOUNG, NPI 1346408226, CMS profile ID 151911. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346408226?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- JENNIFER SOUNG, NPI 1346408226, CMS profile ID 151911, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1346408226?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
287 matching records · $271,237.24 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 287.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Ortho Dermatologics, a division of Bausch Health US, LLC | $916.91 | 11/13/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849555265 | CMS |
| Lilly USA, LLC | $13.44 | 11/12/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818565563 | CMS |
| Lilly USA, LLC | $125.00 | 11/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819117853 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $92.47 | 11/12/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849555257 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $359.00 | 11/12/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849555259 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $50.00 | 11/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849555269 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $669.56 | 11/12/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849555273 | CMS |
| Lilly USA, LLC | $1,050.00 | 11/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818576887 | CMS |
| Lilly USA, LLC | $2,800.00 | 11/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819117849 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $1,720.00 | 11/10/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849555267 | CMS |
| LEO Pharma Inc. | $6.14 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842260473 | CMS |
| PFIZER INC. | $3.17 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833106685 | CMS |
| Janssen Biotech, Inc. | $675.00 | 11/08/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788138345 | CMS |
| Janssen Scientific Affairs, LLC | $675.00 | 11/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788138425 | CMS |
| Janssen Scientific Affairs, LLC | $1,350.00 | 11/06/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788138423 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $679.25 | 11/04/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849555261 | CMS |
| Regeneron Healthcare Solutions, Inc. | $4,224.00 | 11/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809627549 | CMS |
| Lilly USA, LLC | $21.00 | 11/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818555591 | CMS |
| Lilly USA, LLC | $20.00 | 11/03/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818555593 | CMS |
| Lilly USA, LLC | $5.60 | 11/03/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818576885 | CMS |
| Lilly USA, LLC | $49.00 | 11/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819144727 | CMS |
| Lilly USA, LLC | $10.00 | 11/03/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819144731 | CMS |
| Lilly USA, LLC | $93.61 | 11/03/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819144735 | CMS |
| Regeneron Healthcare Solutions, Inc. | $371.50 | 11/02/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809627547 | CMS |
| Regeneron Healthcare Solutions, Inc. | $318.00 | 10/30/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809627545 | CMS |
| Amgen Inc. | $2,620.00 | 10/27/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826358971 | CMS |
| UCB, Inc. | $12.23 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807467279 | CMS |
| UCB, Inc. | $10,472.50 | 10/25/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469239 | CMS |
| UCB, Inc. | $24.00 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469241 | CMS |
| UCB, Inc. | $110.95 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469244 | CMS |
| UCB, Inc. | $11.74 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469247 | CMS |
| UCB, Inc. | $60.00 | 10/25/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469249 | CMS |
| UCB, Inc. | $15.40 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469253 | CMS |
| UCB, Inc. | $65.35 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807469255 | CMS |
| UCB, Inc. | $13.95 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845288423 | CMS |
| UCB, Inc. | $3.90 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845288427 | CMS |
| UCB, Inc. | $883.69 | 10/25/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845288429 | CMS |
| UCB, Inc. | $8.92 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845288433 | CMS |
| UCB, Inc. | $5.00 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845288483 | CMS |
| UCB, Inc. | $5.55 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845288487 | CMS |
| UCB, Inc. | $3.90 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845288491 | CMS |
| UCB, Inc. | $40.67 | 10/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807472795 | CMS |
| AbbVie Inc. | $96.60 | 10/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796077493 | CMS |
| E.R. Squibb & Sons, L.L.C. | $39.68 | 10/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783449159 | CMS |
| SANOFI-AVENTIS U.S. LLC | $82.31 | 10/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843634937 | CMS |
| UCB, Inc. | $53.17 | 10/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807463509 | CMS |
| Janssen Biotech, Inc. | $39.15 | 10/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788138371 | CMS |
| Lilly USA, LLC | $94.80 | 10/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818565567 | CMS |
| Lilly USA, LLC | $92.08 | 10/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818576891 | CMS |
| UCB, Inc. | $135.00 | 10/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807464569 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $6,356.76 | 4 |
| PY2025 | Principal investigator | $988,790.42 | 131 |
| PY2024 | Recipient | $5,410.00 | 4 |
| PY2024 | Principal investigator | $1,115,200.17 | 403 |
| PY2023 | Recipient | $9,880.00 | 12 |
| PY2023 | Principal investigator | $777,498.70 | 155 |
| PY2022 | Recipient | $3,122.00 | 3 |
| PY2022 | Principal investigator | $710,481.87 | 72 |
| PY2021 | Recipient | $259.00 | 1 |
| PY2021 | Principal investigator | $1,284,621.55 | 124 |
| PY2020 | Recipient | $2,449.80 | 2 |
| PY2020 | Principal investigator | $1,267,758.63 | 139 |
| PY2019 | Recipient | $15,369.36 | 4 |
| PY2019 | Principal investigator | $1,338,754.61 | 120 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
135 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $18,997.00 | 12/31/2025 | Non-covered Recipient Entity SOUTHERN CALIFORNIA DERMATOLOGY INC | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202535239 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,981.00 | 12/25/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442063 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,212.00 | 12/25/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442148 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,943.00 | 12/19/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442069 |
| Recipient | PFIZER INC. | $3,200.00 | 12/18/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228810886 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,263.00 | 12/08/2025 | Non-covered Recipient Entity J Robert West M D Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226084212 |
| Principal investigator 1 | ABBVIE INC. | $6,455.70 | 12/04/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202527620 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,914.00 | 12/01/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442037 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,538.00 | 12/01/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442081 |
| Principal investigator 1 | ABBVIE INC. | $5,197.22 | 11/05/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202521481 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,928.00 | 11/03/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442130 |
| Recipient | Amgen Inc. | $1,886.76 | 10/29/2025 | Covered Recipient Physician | A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or = 1 Conventional Synthetic DMARD | No dispute reported | 06/30/2026 | 1246636952 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $105,039.05 | 10/28/2025 | Non-covered Recipient Entity SOUTHERN CALIFORNIA DERMATOLOGY | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190307153 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,446.00 | 10/27/2025 | Non-covered Recipient Entity J Robert West M D Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226084183 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,914.00 | 10/24/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442075 |
| Principal investigator 1 | ABBVIE INC. | $10,516.12 | 10/09/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202514393 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,538.00 | 09/29/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442109 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,212.00 | 09/29/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442118 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,671.00 | 09/29/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442141 |
| Principal investigator 1 | PFIZER INC. | $1,550.00 | 09/11/2025 | Non-covered Recipient Entity J Robert West MD Inc | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228707974 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,175.00 | 09/08/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442136 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,054.00 | 09/08/2025 | Non-covered Recipient Entity J Robert West M D Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226084126 |
| Principal investigator 1 | ABBVIE INC. | $10,752.50 | 09/04/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202509952 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,334.00 | 09/04/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442015 |
| Recipient | PFIZER INC. | $940.00 | 08/29/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228810913 |
| Principal investigator 1 | PFIZER INC. | $1,550.00 | 08/11/2025 | Non-covered Recipient Entity J Robert West MD Inc | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228707970 |
| Principal investigator 1 | ABBVIE INC. | $5,433.60 | 08/06/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202503351 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,596.00 | 08/04/2025 | Non-covered Recipient Entity J Robert West M D Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226084097 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,966.00 | 07/28/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442086 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,271.00 | 07/28/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442154 |
| Principal investigator 1 | PFIZER INC. | $1,550.00 | 07/16/2025 | Non-covered Recipient Entity J Robert West MD Inc | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228707794 |
| Principal investigator 1 | PFIZER INC. | $1,550.00 | 07/16/2025 | Non-covered Recipient Entity J Robert West MD Inc | PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1228707972 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,920.00 | 07/14/2025 | Non-covered Recipient Entity J Robert West M D Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226084073 |
| Principal investigator 1 | ABBVIE INC. | $7,224.52 | 07/08/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497446 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,113.00 | 06/27/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442166 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,299.00 | 06/26/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442170 |
| Principal investigator 1 | Eli Lilly and Company | $46,367.00 | 06/19/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187886008 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $65,084.00 | 06/16/2025 | Non-covered Recipient Entity J Robert West M D Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226084048 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,171.00 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179590 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,668.00 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179613 |
| Principal investigator 1 | Janssen Research & Development, LLC | $312.00 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179621 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,769.80 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179658 |
| Principal investigator 1 | Janssen Research & Development, LLC | $362.00 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179719 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,769.80 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179743 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,668.00 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179752 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179795 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179827 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179845 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179881 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,171.40 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179889 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179917 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,374.80 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179924 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,668.00 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179933 |
| Principal investigator 1 | Janssen Research & Development, LLC | $603.00 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179955 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,374.80 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,769.80 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179997 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180012 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,171.40 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180034 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180050 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180075 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,668.00 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180107 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,667.60 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180114 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,769.80 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180167 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180207 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,171.00 | 06/04/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180215 |
| Principal investigator 1 | ABBVIE INC. | $7,346.20 | 06/03/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202488773 |
| Principal investigator 1 | PFIZER INC. | $12,435.00 | 05/29/2025 | Non-covered Recipient Entity J Robert West MD Inc | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228840023 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,300.00 | 05/27/2025 | Non-covered Recipient Entity J Robert West M D Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226084041 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,879.00 | 05/26/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442057 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,371.00 | 05/22/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442031 |
| Principal investigator 1 | ABBVIE INC. | $19,752.60 | 05/07/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202483937 |
| Principal investigator 1 | ABBVIE INC. | $1,890.90 | 05/06/2025 | Non-covered Recipient Entity SOUTHERN CALIFORNIA DERMATOLOGY INC | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202482185 |
| Recipient | PFIZER INC. | $330.00 | 05/06/2025 | Covered Recipient Physician | RITLECITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838482 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,323.00 | 04/28/2025 | Non-covered Recipient Entity Sthrn California Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175180090 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,002.00 | 04/28/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442044 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,879.00 | 04/28/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442124 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,107.00 | 04/21/2025 | Non-covered Recipient Entity J Robert West M D Inc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226084020 |
| Principal investigator 1 | ABBVIE INC. | $8,702.88 | 04/03/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202470982 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,950.00 | 04/02/2025 | Non-covered Recipient Entity J Robert West M D Inc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226083992 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,256.00 | 04/02/2025 | Non-covered Recipient Entity J Robert West M D Inc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226084003 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,938.00 | 03/27/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442098 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,939.00 | 03/24/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442024 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179598 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179630 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,557.30 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179668 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179684 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179693 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179708 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179812 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179835 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179865 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179898 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179942 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179989 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,557.30 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180026 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180058 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,044.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180097 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180122 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180128 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180136 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180147 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180153 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180190 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180198 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180233 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180240 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 03/12/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180258 |
| Principal investigator 1 | ABBVIE INC. | $15,363.12 | 03/07/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202459874 |
| Principal investigator 1 | ABBVIE INC. | $2,121.90 | 03/06/2025 | Non-covered Recipient Entity SOUTHERN CALIFORNIA DERMATOLOGY INC | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202456897 |
| Principal investigator 1 | Janssen Research & Development, LLC | $48,232.00 | 03/05/2025 | Non-covered Recipient Entity Sthrn California Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175179677 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,908.00 | 03/04/2025 | Non-covered Recipient Entity J Robert West M D Inc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226084000 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,646.00 | 03/03/2025 | Non-covered Recipient Entity Sthrn California Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175180174 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,830.00 | 03/03/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442051 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,777.00 | 03/03/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442177 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,541.00 | 02/27/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179640 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,541.00 | 02/27/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179777 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,541.00 | 02/27/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179872 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,541.00 | 02/27/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175179982 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,759.00 | 02/07/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442160 |
| Principal investigator 1 | ABBVIE INC. | $13,405.11 | 02/06/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202449286 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,200.00 | 02/05/2025 | Non-covered Recipient Entity Sthrn California Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175179909 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 02/05/2025 | Non-covered Recipient Entity Sthrn California Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175179973 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,095.00 | 02/04/2025 | Non-covered Recipient Entity J Robert West M D Inc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226083980 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,541.00 | 01/27/2025 | Non-covered Recipient Entity J Robert W MD Inc. | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175180005 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,300.00 | 01/27/2025 | Non-covered Recipient Entity J Robert West M D Inc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226083976 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,372.00 | 01/24/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442093 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $81,174.00 | 01/24/2025 | Non-covered Recipient Entity J Robert West M D Inc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226083972 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,057.00 | 01/16/2025 | Non-covered Recipient Entity Sthrn California Derm | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175179702 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,870.00 | 01/09/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175442103 |
| Principal investigator 1 | Eli Lilly and Company | $53,964.70 | 01/07/2025 | Non-covered Recipient Entity J ROBERT WEST MD INC | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187883756 |
| Principal investigator 1 | ABBVIE INC. | $1,851.90 | 01/02/2025 | Non-covered Recipient Entity SOUTHERN CALIFORNIA DERMATOLOGY INC | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202435689 |